This product is a new-generation preventive vaccine formulated using a highly stable pre-F antigen sequence as the encoding antigen for mRNA and the mRNA-LNP (Lipid Nanoparticle) technology platform. It is intended for individuals aged 60 years and above, aiming to prevent acute RSV infection and associated severe lower respiratory tract diseases.
Preclinical animal studies have demonstrated its good immunogenicity. It activates strong humoral immunity and dominant cellular immune responses; in addition to protective neutralizing antibodies, its designed ability to induce robust cellular immune responses represents a unique advantage in enhancing immune capacity in the elderly and immunocompromised populations.
The production of toxicology batches and three GMP batches has been completed. Preclinical safety studies and cotton rat challenge protection studies have also been finished, showing good safety with no observed risk of vaccine-enhanced disease (VED). It is planned to submit Investigational New Drug (IND) applications to China's National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) in Q4 2025.

For all the above-mentioned products, we are seeking localized cooperation, technology transfer, and agency partnerships in overseas markets.